Literature DB >> 6277763

Primary hepatocellular carcinoma--etiology, pathogenesis, and prevention.

W T London.   

Abstract

Worldwide, primary hepatocellular carcinoma may be the most common cancer in men. Usually it occurs in association with cirrhosis or chronic hepatitis. In this article I present evidence that the majority of these cases are associated with, and probably caused by, persistent infection with hepatitis B virus. I also propose a model that describes the role of the hepatitis B virus in the pathogenesis of primary hepatocellular carcinoma. If persistent infection with hepatitis B virus is required for the development of most cases of primary hepatocellular carcinoma, prevention of such infections should prevent most cases of primary hepatocellular carcinoma. A vaccine against hepatitis B virus, prepared from surface antigen particles (HBsAg) harvested from the blood of hepatitis B virus carriers, has been safe and effective in preventing acute infection with hepatitis B virus in adult homosexual men. If it is equally safe and effective in young children, it will be administered widely to populations living in areas endemic for hepatitis B virus infections. Thereafter it may be possible to learn within five to 10 years whether the vaccine prevents chronic liver disease. If it does, it will be reasonable to conclude that it will also prevent primary hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6277763     DOI: 10.1016/s0046-8177(81)80329-2

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  17 in total

1.  Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity.

Authors:  G M Ginsberg; D Shouval
Journal:  J Epidemiol Community Health       Date:  1992-12       Impact factor: 3.710

2.  Vortex mixing catheter.

Authors:  J R Shanebrook; K B Tillotson; B L Weick
Journal:  Med Biol Eng Comput       Date:  1992-01       Impact factor: 2.602

3.  Two genes abrogate the inhibition of murine hepatocarcinogenesis by ovarian hormones.

Authors:  T M Poole; N R Drinkwater
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

4.  Ablation of recurrent primary liver cancer using 131I-lipiodol.

Authors:  R Novell; A Hilson; K Hobbs
Journal:  Postgrad Med J       Date:  1991-04       Impact factor: 2.401

Review 5.  Hepatocellular carcinoma. A worldwide problem and the major risk factors.

Authors:  R G Simonetti; C Cammà; F Fiorello; F Politi; G D'Amico; L Pagliaro
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

6.  Enhancement of hepatocarcinogenesis in rainbow trout with carbon tetrachloride.

Authors:  N Kotsanis; C D Metcalfe
Journal:  Bull Environ Contam Toxicol       Date:  1991-06       Impact factor: 2.151

7.  Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs.

Authors:  M G van Ijken; E A de Bruijn; G de Boeck; T L ten Hagen; J R van der Sijp; A M Eggermont
Journal:  Ann Surg       Date:  1998-12       Impact factor: 12.969

8.  Loss of heterozygosity suggests tumor suppressor gene responsible for primary hepatocellular carcinoma.

Authors:  K H Buetow; J C Murray; J L Israel; W T London; M Smith; M Kew; V Blanquet; C Brechot; A Redeker; S Govindarajah
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

9.  Liver transplantation for hepatocellular carcinoma: the ochsner experience.

Authors:  George E Loss; Satheesh Nair; Jamie L Blazek; Gist H Farr; James D Eason
Journal:  Ochsner J       Date:  2002

10.  A substituted tetrahydro-tetrazolo-pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion.

Authors:  Anne Marie Dougherty; Haitao Guo; Gael Westby; Yuanjie Liu; Ender Simsek; Ju-Tao Guo; Anand Mehta; Pamela Norton; Baohua Gu; Timothy Block; Andrea Cuconati
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.